
Benefits
Cognitive Enhancement and Neuroprotection
Citicoline boosts acetylcholine production and supports neuronal membrane repair, potentially improving memory, focus, and cognitive function in healthy individuals and those with mild cognitive impairment or neurodegenerative diseases.
Stroke Recovery
Citicoline aids post-ischemic stroke recovery by promoting brain repair and enhancing neuroplasticity, with studies showing improved functional outcomes when given soon after a stroke.
Brain Injury and Trauma
By reducing inflammation and supporting neuronal repair, citicoline may improve cognitive and neurological recovery in cases of traumatic brain injury or concussion.
Eye Health (Glaucoma and Optic Neuropathy)
Citicoline protects retinal cells and improves visual function, often used as an adjunct therapy to enhance outcomes in glaucoma or optic neuropathy.
Mood and Mental Health
Citicoline may support mood regulation by influencing dopamine and acetylcholine levels, showing preliminary benefits for depression or bipolar disorder.
Attention and Focus (e.g., ADHD)
Citicoline may enhance attention and reduce impulsivity, with small studies suggesting benefits for individuals with ADHD.
Energy Metabolism in the Brain
By supporting mitochondrial function and ATP production, citicoline enhances brain energy metabolism, potentially aiding cognitive and neuroprotective effects.
Addiction and Substance Abuse
Citicoline may reduce cravings and support recovery from substance abuse, such as cocaine or alcohol, by modulating dopamine pathways.
Mechanism of Action
Precursor to Phosphatidylcholine Synthesis
Citicoline provides cytidine and choline, which are used to synthesize phosphatidylcholine, a key component of neuronal membranes, supporting their repair and integrity.
Acetylcholine Production
Citicoline serves as a choline source, increasing acetylcholine synthesis, a neurotransmitter essential for memory, learning, and cognitive function.
Neuroprotection and Anti-Apoptosis
By reducing oxidative stress and inhibiting neuronal apoptosis, citicoline protects brain cells from damage in conditions like stroke or traumatic brain injury.
Enhances Neuroplasticity
Citicoline promotes synaptic repair and neuroplasticity by supporting phospholipid synthesis and increasing brain-derived neurotrophic factor (BDNF) expression.
Modulates Neurotransmitter Systems
Citicoline influences dopamine and serotonin pathways, potentially improving mood, attention, and reducing cravings in addiction.
Boosts Mitochondrial Energy Production
Citicoline enhances ATP production and mitochondrial function, improving brain energy metabolism to support cognitive and neurological health.
Reduces Inflammation
Citicoline decreases pro-inflammatory cytokines and stabilizes cell membranes, mitigating inflammation in the brain and other tissues.
Supports Retinal Ganglion Cell Function
By providing phospholipids and reducing oxidative damage, citicoline protects retinal cells, enhancing visual function in conditions like glaucoma.
Clinical Trials
Citicoline in the Treatment of Acute Ischaemic Stroke: An International, Randomised, Multicentre, Placebo-Controlled Study (ICTUS Trial)
Study: This 2012 international, randomized, double-blind, placebo-controlled trial (NCT01189045) involved 2,298 patients with moderate-to-severe acute ischemic stroke (AIS) within 24 hours of onset. Patients received 2,000 mg/day citicoline (1,000 mg IV every 12 hours for 3 days, then 1,000 mg oral twice daily) or placebo for 6 weeks. The primary endpoint was global recovery at 90 days (combined NIHSS ≤1, mRS ≤1, and Barthel Index ≥95).
Findings: Citicoline showed no significant benefit over placebo for global recovery (odds ratio [OR] 1.03, 95% CI 0.86–1.25, p=0.364). Subgroup analyses suggested potential benefits in patients over 70, those with NIHSS <14, or those not receiving thrombolytic therapy, but the overall trial concluded citicoline was not efficacious for AIS. Side effects were similar between groups, with mild digestive disturbances in <5%.
Link: The Lancet
Citicoline Brain Injury Treatment Trial (COBRIT)
Study: This 2012 phase III, double-blind, randomized, placebo-controlled trial (NCT00545662) involved 1,213 patients with traumatic brain injury (TBI) classified as complicated mild, moderate, or severe. Patients received 2,000 mg/day oral citicoline or placebo for 90 days. Outcomes included functional and cognitive status assessed by the TBI Clinical Trials Network Core Battery, including Glasgow Outcome Scale–Extended (GOS-E).
Findings: Citicoline did not significantly improve functional or cognitive outcomes compared to placebo at 90 days (OR 0.98, 95% CI 0.83–1.15) or 180 days (OR 0.87, 95% CI 0.72–1.04). Improvements in GOS-E were similar (35.4% citicoline vs. 35.6% placebo). The treatment was safe, with rare mild side effects (e.g., diarrhea, headache).
Link: JAMA
Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Study: This 2021 randomized, double-blind, placebo-controlled trial involved 100 healthy older adults (aged 50–85) with age-associated memory impairment (AAMI). Participants received 500 mg/day Cognizin® citicoline or placebo for 12 weeks. Outcomes included memory performance (episodic and overall memory) assessed using standardized tests like the Paired Associates and Logical Memory subtests.
Findings: Citicoline significantly improved overall memory performance (p<0.05), particularly episodic memory, compared to placebo. Motor speed and reduced impulsivity were also noted. The supplement was well-tolerated with no serious adverse effects.
Link: The Journal of Nutrition
Effectiveness and Safety of Citicoline in Mild Vascular Cognitive Impairment: The IDEALE Study
Study: This 2013 open-label, non-randomized, parallel trial involved 349 patients with mild vascular cognitive impairment. Patients received 1,000 mg/day citicoline (500 mg twice daily) or no treatment for 9 months. Outcomes included Mini-Mental State Examination (MMSE) scores, activities of daily living, and brain MRI changes.
Findings: Citicoline improved MMSE scores (p<0.05) compared to the control group, which showed a decline. Functional and cognitive improvements were sustained at 9 months. No significant adverse effects were reported, though the non-randomized design limits conclusions.
Link: Clinical Interventions in Aging
Double-Blind Placebo-Controlled Study with Citicoline in APOE Genotyped Alzheimer’s Disease Patients: Effects on Cognitive Performance, Brain Bioelectrical Activity, and Cerebral Perfusion
Study: This 1999 randomized, double-blind, placebo-controlled trial involved 30 Alzheimer’s disease patients stratified by APOE genotype. Participants received 1,000 mg/day citicoline or placebo for 12 weeks. Outcomes included cognitive performance (ADAS-Cog), EEG activity, and cerebral blood flow (SPECT).
Findings: Citicoline improved cognitive performance (ADAS-Cog, p<0.05) and increased cerebral blood flow, particularly in APOE ε4 non-carriers. EEG showed improved brain bioelectrical activity. No significant side effects were reported.
Link: Methods and Findings in Experimental and Clinical Pharmacology
A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder
Study: This 2015 randomized, double-blind, placebo-controlled trial involved 130 outpatients with bipolar I disorder and cocaine dependence. Participants received 2,000 mg/day citicoline or placebo for 12 weeks alongside standard treatment. Outcomes included cocaine use (urine tests) and mood symptoms (Hamilton Depression Rating Scale).
Findings: Citicoline significantly reduced cocaine use (p=0.026) compared to placebo, with no significant effect on mood symptoms. The treatment was well-tolerated, with mild side effects (e.g., stomach pain) in <10% of participants.
Link: American Journal of Psychiatry
Can Treatment with Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-Controlled Clinical Trial
Study: This 2020 randomized, double-blind, placebo-controlled trial involved 78 patients with progressive glaucoma. Participants received 2% citicoline eyedrops or placebo three times daily for 3 years. Outcomes included visual field progression and retinal function (pattern electroretinogram, PERG).
Findings: Citicoline eyedrops significantly reduced visual field progression (p<0.05) and improved PERG amplitudes compared to placebo, suggesting neuroprotective effects. No significant ocular or systemic side effects were reported.
Link: Journal of Glaucoma
Assessing the Acute Effects of CDP-Choline on Sensory Gating in Schizophrenia: A Pilot Study
Study: This 2018 randomized, double-blind, placebo-controlled, crossover trial involved 24 healthy males (mean age 21.3) to assess citicoline’s effects on sensory gating and cognition. Participants received a single dose of 500 mg or 1,000 mg citicoline or placebo. Outcomes included P50 event-related potential (ERP) suppression and EEG oscillations.
Findings: Citicoline (500 mg and 1,000 mg) improved sensory gating (P50 suppression, p<0.05) and EEG oscillations, particularly in low-gating individuals, suggesting potential benefits for schizophrenia-related cognitive deficits. No adverse effects were reported.
Link: Journal of Psychopharmacology
Citicoline on the Barthel Index: Severe and Moderate Brain Injury
Study: This 2023 randomized, controlled trial involved 40 patients with severe or moderate TBI. Patients received 2,000 mg/day citicoline or standard treatment for 14 days. Outcomes included Barthel Index scores, NIHSS, and Glasgow Coma Scale (GCS).
Findings: Citicoline significantly improved Barthel Index scores (p=0.02) and NIHSS (p=0.03) compared to controls, indicating better functional recovery. No significant differences in GCS or adverse effects were noted.
Link: Indian Journal of Pharmacology
Efficacy of Citicoline as a Neuroprotector in Children with Post-Cardiac Arrest: A Randomized Controlled Clinical Trial
Study: This 2021 randomized, controlled trial involved 60 children post-cardiac arrest. Patients received 100 mg/kg/day citicoline IV or placebo for 7 days. Outcomes included neurological status (Pediatric Cerebral Performance Category, PCPC) and survival at 3 months.
Findings: We found that Citicoline is a promising neuroprotective drug in children with post-cardiac arrest.
Link: Pubmed
Potential Side Effects
Gastrointestinal Discomfort
Citicoline may cause mild nausea, diarrhea, or stomach upset, particularly at higher doses.
Headache
Some users report headaches, likely due to increased acetylcholine levels affecting the nervous system.
Insomnia
Citicoline’s stimulatory effects on brain activity may lead to difficulty sleeping in some individuals.
Low Blood Pressure
Rare cases of hypotension may occur, possibly linked to citicoline’s effects on vascular function.
Dizziness or Fatigue
Mild dizziness or fatigue can occur, potentially due to changes in neurotransmitter activity.
Allergic Reactions
Rare allergic responses, such as rash or itching, may occur, especially in those sensitive to citicoline’s source ingredients.
Heart Palpitations
High doses may cause palpitations in sensitive individuals, possibly from excessive choline metabolism.
Mood Changes
Some users may experience irritability or mood swings, likely due to altered dopamine or acetylcholine levels.